Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation [Clinical Sciences]
Conclusions—
In patients with nonvalvular atrial fibrillation and an increased risk of stroke prophylaxis, apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg were all cost-effective alternatives to warfarin. The cost-effectiveness of novel oral anticoagulantss was dependent on therapy pricing in the United States and neurological events associated with rivaroxaban 20 mg.
Source: Stroke - Category: Neurology Authors: Harrington, A. R., Armstrong, E. P., Nolan, P. E., Malone, D. C. Tags: Other anticoagulants, Embolic stroke, Anticoagulants Clinical Sciences Source Type: research
More News: Atrial Fibrillation | Clinical Trials | Coumadin | Neurology | Pradaxa | Stroke | Warfarin